Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Clinical trial NCT02962063 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02962063
Sponsor: Memorial Sloan Kettering Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Esophageal Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

Start date: 2016-11-01
Primary completion: 2026-11-01
Enrollment: 64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.